優通未來(06168.HK):獲准下月15日召開計劃會議
優通未來(06168.HK)公布,召開計劃會議之首次聆訊已於昨日(8日)在香港法院進行。香港法院已發出命令批准公司可根據其條款於2023年3月15日召開計劃會議。因此,公司將根據該命令之條款落實召開計劃會議。此外,假設債權人將在計劃會議上批准香港計劃,並視乎上市覆核委員會覆核結果,香港法院舉行第二次聆訊的日期已暫定為2023年5月23日,藉以就公司計劃提出申請批准香港計劃、永久擱置清盤令,並解除清盤人職務進行聆訊。
另外,集團表示,終止認購協議後,昨天已註銷約4.17億股,已發行股份數目降至約24.43億股。該集團自2021年5月5日起停牌,並將繼續暫停買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.